70
Participants
Start Date
May 11, 2023
Primary Completion Date
November 30, 2027
Study Completion Date
November 30, 2030
Fludarabine
Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
Busulfan
Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
Melphalan
Melphalan 50 mg/m2 IV on days -4 to -2
Rituximab
200 mg/m2 intravenous given once on day-1
Levetiracetam
As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
Thymoglobulin
rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.
Cyclophosphamide
Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2
RECRUITING
University of Minnesota Masonic Cancer Center, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER